TP53 in biology and treatment of osteosarcoma
KJ Synoradzki, E Bartnik, AM Czarnecka… - Cancers, 2021 - mdpi.com
Simple Summary Treatment of osteosarcoma, apart from chemotherapy modifications, has
not changed for approximately 30 years. Similarly, as in other tumors, mutations in the TP53 …
not changed for approximately 30 years. Similarly, as in other tumors, mutations in the TP53 …
Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells
J Tong, P Wang, S Tan, D Chen, Z Nikolovska-Coleska… - Cancer research, 2017 - AACR
Abstract The Bcl-2 family protein Mcl-1 is often degraded in cancer cells subjected to
effective therapeutic treatment, and defective Mcl-1 degradation has been associated with …
effective therapeutic treatment, and defective Mcl-1 degradation has been associated with …
PUMA is a novel target of miR-221/222 in human epithelial cancers
C Zhang, J Zhang, A Zhang… - International …, 2010 - spandidos-publications.com
miR-221 and miR-222 (miR-221/222) are frequently up-regulated in human epithelial
cancers. However, the mechanism of miR-221/222 action involved in carcinogenesis has …
cancers. However, the mechanism of miR-221/222 action involved in carcinogenesis has …
The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage
The tumor suppressor p53 can induce apoptosis by activating gene expression in the
nucleus, or by directly permeabilizing mitochondria in the cytoplasm. It has been shown that …
nucleus, or by directly permeabilizing mitochondria in the cytoplasm. It has been shown that …
Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis
Purpose: Regorafenib, a multikinase inhibitor targeting the Ras/Raf/MEK/ERK pathway, has
recently been approved for the treatment of metastatic colorectal cancer. However, the …
recently been approved for the treatment of metastatic colorectal cancer. However, the …
mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation
The mammalian target of rapamycin (mTOR) is commonly activated in colon cancer. mTOR
complex 1 (mTORC1) is a major downstream target of the PI3K/ATK pathway and activates …
complex 1 (mTORC1) is a major downstream target of the PI3K/ATK pathway and activates …
Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy
JH Xu, SL Hu, GD Shen, G Shen - Cancer cell international, 2016 - Springer
Objectives Paclitaxel (PTX) is frequently used in the clinical treatment of solid tumors. But the
PTX-resistance is a great obstacle in cancer treatment. Exploration of the mechanisms of …
PTX-resistance is a great obstacle in cancer treatment. Exploration of the mechanisms of …
[HTML][HTML] The role of ROS and subsequent DNA-damage response in PUMA-induced apoptosis of ovarian cancer cells
J Yang, X Zhao, M Tang, L Li, Y Lei, P Cheng, W Guo… - Oncotarget, 2017 - ncbi.nlm.nih.gov
PUMA is a member of the “BH3-only” branch of the BCL-2 family. Our previous study
suggests a therapeutic potential of PUMA in treating ovarian cancer, however, the action …
suggests a therapeutic potential of PUMA in treating ovarian cancer, however, the action …
[HTML][HTML] MicroRNAs in lung cancer
P Joshi, J Middleton, YJ Jeon… - World journal of …, 2014 - ncbi.nlm.nih.gov
MicroRNAs have become recognized as key players in the development of cancer. They are
a family of small non-coding RNAs that can negatively regulate the expression of cancer …
a family of small non-coding RNAs that can negatively regulate the expression of cancer …